Trends in Pharmacological Sciences
ReviewMissing the target: matrix metalloproteinase antitargets in inflammation and cancer
Section snippets
MMPs as inflammation and cancer drug targets
MMPs were identified as cancer drug targets (see Glossary) more than 30 years ago. At this time, MMP1, MMP2, and MMP3 were the only MMPs known and the therapeutic strategy was focused on inhibiting the degradation of the extracellular matrix (ECM) proteins that facilitate metastasis and angiogenesis 1, 2. The first anticancer MMP inhibitors were peptidomimetics that were not orally available (e.g., Batimastat, BB94; Ilomastat, GM-6001) and these were followed by improved second-generation
MMPs as drug antitargets
Human studies ultimately are the most relevant test of the efficacy of blocking a drug target. From the failure of broad-spectrum MMP inhibitors in cancer clinical trials, we have learned that: (i) in tumors, MMPs are produced by both the cancer cells and the surrounding stromal cells, and infiltrate inflammatory and immune cells; (ii) the role of MMPs differs according to the stage of cancer; and (iii) some MMPs are antitargets. Drug antitargets are molecules with essential normal roles in
Intertwining of cancer with inflammation
Cancer and inflammation are intertwined [27]. Thus, as the tumor inflammatory component increases tumorigenicity or metastasis, anti-inflammatory roles for MMPs potentially are also antitumorigenic and antimetastatic. Therefore, it is unsurprising that many MMPs can also interfere with cancer progression (Table 1). Since the first review of unexpected anticancer roles for MMPs [2], other examples of anticancer mechanisms have been reported. Some of these observations are strictly model
Sifting through MMP roles in vivo to uncover beneficial and detrimental activities
To reveal the protease substrate repertoire and hence the biological role for a MMP in a specific disease or particular organ, or to shed light on the temporal aspects of the role, one approach is to study the substrate degradome of the MMP. Theoretical activities inferred from cell culture (2D or 3D) or in vitro experiments can differ greatly in the more complex in vivo milieu in which all proteins and mediators are present at relevant concentrations [37]. With the recent advent of
Think inside the box
Multiple MMPs have been described as both targets and antitargets – so are MMPs friends or foes? Is our current view of the roles of MMPs becoming blurrier or clearer? Erwin Schrödinger designed a thought experiment – a paradox – using everyday objects to illustrate his view of quantum mechanics. The scenario comprises a cat inside a closed box in which a sealed poison vial is enclosed and can break at any time. An observer can never be sure whether the cat is dead or alive. This example was
Protease web alterations
In addition to the beneficial activities of MMPs that optimally need to be spared in treatment, in recent years new added complexity has become apparent arising from the complicated interconnectivity of protease networks that form a larger protease web embedded in each proteome [2]. Proteases do not act alone in vivo; they activate protease zymogens, as well as inactivating proteases and their inhibitors. By zymogen activation or by inactivating protease inhibitors, such as MMP cleavage of
Proteolytic signatures
How, then, to deal with the intertwined activity of the protease web in vivo interwoven in a melee of substrates, inhibitors, signaling molecules, and cell receptors? Collectively, a ‘proteolytic signature’ can be established to describe the cleaved proteins present in a tissue or cell. Proteomically, this is now possible using N-terminomics techniques such as TAILS and combined fractional diagonal chromatography (COFRADIC) whereby all N termini, both original protein and neo-termini generated
Taking Schrödinger's cat out of the box
There is no doubt that MMPs play crucial roles in various human pathologies, both beneficial and detrimental, but what are the options to address the Schrodinger's cat paradox in the context of MMPs? The failure of MMP inhibitors in Phase III of cancer clinical trials has led to a reevaluation of the diverse biological roles of MMPs. Where is the balance between the target and antitarget properties of MMPs and what are the issues we need to address for the design of effective inhibitors in the
Design of more selective inhibitors
Several groups have developed highly selective small-molecule MMP inhibitors to single MMPs (e.g., MMP12) 42, 52, 53. However, biologicals generally offer the best approach for ultraselective inhibition to date. A promising monoclonal antibody targeted at only the active form of MMP14 was demonstrated to inhibit angiogenesis and slow tumor progression and metastasis in several animal models including orthotopic, subcutaneous, and xenograft murine models 54, 55. However, the precise role of
Target the substrates of MMPs
Proteomic analyses have revealed myriad novel substrates of MMPs. Most of these proteins are involved in inflammatory and immune processes and are not classic components of the ECM. As a strategy to avoid blocking beneficial MMP antitarget activities, drugs targeting the MMP substrate might be a more effective way specifically to treat disease by blocking the responsible substrate activity or masking cleavage sites and thereby sparing MMP antitarget activities. One example could be to target
Concluding remarks
MMPs are clearly established as major players in diverse biological functions and thus remain of immense interest in understanding many homeostatic and pathological processes. Hence, MMPs remain potential drug targets. However, the variety of their substrates and physiological activities means that they can function both as drug targets and as antitargets, which hampers drug development. There are several important remaining questions. Can an MMP be targeted for one disease in which it is known
Glossary
- Anti-target
- a molecule or protein with essential or host protective roles in the normal state of a cell or tissue function. Inhibition of its activity results in clinically unwanted side effects and initiation or worsening of disease.
- Degradomics
- all system-wide genomics, proteomics, and systems biology techniques that study the structural and functional roles of the proteases, inactive homologs, and protease inhibitors that are present in an organism.
- Target
- a molecule or protein that unambiguously
References (84)
Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo
Blood
(2002)- et al.
Clinical studies on the management of periodontal diseases utilizing subantimicrobial dose doxycycline (SDD)
Pharmacol. Res.
(2011) Biochemical analysis of matrix metalloproteinase activation of chemokines CCL15 and CCL23 and increased glycosaminoglycan binding of CCL16
J. Biol. Chem.
(2012)Biochemical characterization and N-terminomics analysis of leukolysin, the membrane-type 6 matrix metalloprotease (MMP25): chemokine and vimentin cleavages enhance cell migration and macrophage phagocytic activities
J. Biol. Chem.
(2012)Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance
J. Biol. Chem.
(1999)Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma
Cell
(1997)Matrix metalloproteinase proteomics: substrates, targets, and therapy
Curr. Opin. Cell Biol.
(2009)Macrophage-specific metalloelastase (MMP-12) truncates and inactivates ELR+ CXC chemokines and generates CCL2, -7, -8, and -13 antagonists: potential role of the macrophage in terminating polymorphonuclear leukocyte influx
Blood
(2008)Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation
J. Biol. Chem.
(2000)Development of selective inhibitors and substrate of matrix metalloproteinase-12
J. Biol. Chem.
(2006)
Insights from selective non-phosphinic inhibitors of MMP-12 tailored to fit with an S1′ loop canonical conformation
J. Biol. Chem.
MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis
Cell
Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin
Cancer Cell
Deficiency of gelatinase B/MMP-9 aggravates lpr-induced lymphoproliferation and lupus-like systemic autoimmune disease
J. Autoimmun.
Matrix metalloproteinase-9 (gelatinase B) deficiency leads to increased severity of Staphylococcus aureus-triggered septic arthritis
Microbes Infect.
Enamelysin (matrix metalloproteinase 20)-deficient mice display an amelogenesis imperfecta phenotype
J. Biol. Chem.
Potassium channel modulation by a toxin domain in matrix metalloprotease 23
J. Biol. Chem.
Absence of mechanical allodynia and Abeta-fiber sprouting after sciatic nerve injury in mice lacking membrane-type 5 matrix metalloproteinase
FEBS Lett.
Overlapping and independent contributions of MMP2 and MMP9 to lung allergic inflammatory cell egression through decreased CC chemokines
FASEB J.
Tumour microenvironment — opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy
Nat. Rev. Cancer
Matrix metalloproteinase inhibitors and cancer: trials and tribulations
Science
Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment
Oncogene
Matrix metalloproteinases as modulators of inflammation and innate immunity
Nat. Rev. Immunol.
Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3
Science
Cytokine substrates: MMP regulation of inflammatory signaling molecules
Macrophage elastase kills bacteria within murine macrophages
Nature
Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense
Science
Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases
Nat. Rev. Drug Discov.
Loss of collagenase-2 confers increased skin tumor susceptibility to male mice
Nat. Genet.
Altered metastatic behavior of human breast cancer cells after experimental manipulation of matrix metalloproteinase 8 gene expression
Cancer Res.
Collagenase-2 (matrix metalloproteinase-8) plays a protective role in tongue cancer
Br. J. Cancer
Matrix metalloproteinase-8 deficiency increases joint inflammation and bone erosion in the K/BxN serum-transfer arthritis model
Arthritis Res. Ther.
Matrix metalloproteinase 8 deficiency in mice exacerbates inflammatory arthritis through delayed neutrophil apoptosis and reduced caspase 11 expression
Arthritis Rheum.
Matrix metalloproteinase-8 inactivates macrophage inflammatory protein-1 alpha to reduce acute lung inflammation and injury in mice
J. Immunol.
Matrix metalloproteinase-8 deficiency promotes granulocytic allergen-induced airway inflammation
J. Immunol.
LPS responsiveness and neutrophil chemotaxis in vivo require PMN MMP-8 activity
PLoS ONE
Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP2-deficiency
Nat. Immunol.
Isotopic labeling of terminal amines in complex samples identifies protein N-termini and protease cleavage products
Nat. Biotechnol.
Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting
Nat. Rev. Drug Discov.
Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases
Crit. Rev. Biochem. Mol. Biol.
Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing
N. Engl. J. Med.
A protective role for matrix metalloproteinase-3 in squamous cell carcinoma
Cancer Res.
Cited by (268)
Fibroblasts in Orchestrating Colorectal Tumorigenesis and Progression
2024, Cellular and Molecular Gastroenterology and HepatologyMetalloproteins and metalloproteomics in health and disease
2024, Advances in Protein Chemistry and Structural BiologyScientific and clinical relevance of non-cellular tumor microenvironment components in ovarian cancer chemotherapy resistance
2024, Biochimica et Biophysica Acta - Reviews on CancerETV4 facilitates angiogenesis in hepatocellular carcinoma by upregulating MMP14 expression
2023, Biochemical and Biophysical Research CommunicationsNegative enrichment strategy combined with site-specific derivatization for the C-terminomics
2023, Journal of ProteomicsMatrix Metalloproteinase-1 Expression in Fibroblasts Accelerates Dermal Aging and Promotes Papilloma Development in Mouse Skin
2023, Journal of Investigative Dermatology